Prostatakarzinom und Ernährung

Stanley A Brosman | 12. Juni 2012

Autoren und Interessenskonflikte

Ernährungstherapie des Prostatakarzinoms

Ornish et al zeigten, dass die Änderung des Lebensstils im Sinne einer Umstellung auf eine vegane Ernährung, einer Nahrungsergänzung mit Antioxidantien, gymnastischen Übungen und Techniken zur Stressminimierung bei Männern mit „low-risk“ Prostatakarzinom den PSA-Wert m 0,25ng/ml (4%) senken kann (35). Allerdings bedeutet ein Absinken des PSA nicht immer, dass Karzinomzellen inaktiv geworden sind.

Veränderungen der Ernährungsgewohnheiten verbunden mit körperlicher Betätigung und Modifikationen des Lebensstils können die Tumorwachstumsraten beeinflussen. Diese Maßnahmen können in Einklang mit einer akzeptierten Therapie eingesetzt werden. Eine alleinige Ernährungsumstellung als Therapie des Prostatakarzinoms ist nicht vertretbar.

9 von 9


  1. Huang HY. Customized diets for cancer prevention according to genetic polymorphisms: are we ready yet?. J Natl Cancer Inst. Nov 15 2006;98(22):1590-1.
  2. K BE, C C, J B, et al. Predictors of cancer survivors' receptivity to lifestyle behavior change interventions. Cancer Epidemiol Biomarkers Prev. Feb 15 2012;
  3. Tannenbaum, A. Cancer Res. The genesis and growth of tumors. III: Effects of a high fat diet. 1942;2:468-475.
  4. Committee on Diet, Nutrition and Cancer, Assembly of Life Sciences, National Research Council. Diet, Nutrition and Cancer. Washington, DC: National Academy; 1982.
  5. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. May 3 1995;87(9):652-61.
  6. Kolonel LN, Hankin JH, Lee J, Chu SY, Nomura AM, Hinds MW. Nutrient intakes in relation to cancer incidence in Hawaii. Br J Cancer. Sep 1981;44(3):332-9.
  7. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. Oct 6 1993;85(19):1571-9.
  8. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. Oct 4 1995;87(19):1456-62.
  9. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. Jan 25 2006;295(4):403-15.
  10. Ritch CR, Wan RL, Stephens LB, Taxy JB, Huo D, Gong EM, et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol. Jan 2007;177(1):97-101; discussion 101.
  11. Wright ME, Bowen P, Virtamo J, et al. Estimated phytanic acid intake and prostate cancer risk: A prospective cohort study. Int J Cancer. Nov 28 2011;
  12. Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RB, et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res. Dec 15 2005;65(24):11779-84.
  13. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst. Mar 17 1999;91(6):512-23.
  14. Huffman DM, Johnson MS, Watts A, Elgavish A, Eltoum IA, Nagy TR. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake. Cancer Res. Jan 1 2007;67(1):417-24.
  15. Klein EA, Casey G, Silverman R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology. Dec 2006;68(6):1145-51.
  16. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. Feb 28 2007;297(8):842-57.
  17. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. Oct 12 2011;306(14):1549-56.
  18. [Best Evidence] Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. Jan 7 2009;301(1):52-62.
  19. Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon-Cardo C, et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev. Jul 2001;10(7):749-56.
  20. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res. Jan 15 2007;67(2):836-43.
  21. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. Jan 7 2009;301(1):39-51.
  22. Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, et al. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate. May 1 2007;67(6):582-90.
  23. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. Mar 18 1998;90(6):440-6.
  24. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. Apr 5 2006;98(7):451-9.
  25. de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int. Nov 1999;84(7):845-50.
  26. Nagao M, Honda M, Seino Y, Yahagi T, Sugimura T. Mutagenicities of smoke condensates and the charred surface of fish and meat. Cancer Lett. Mar 1977;2(4-5):221-6.
  27. Knize MG, Felton JS. Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat. Nutr Rev. May 2005;63(5):158-65.
  28. Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. Feb 1 2007;67(3):1378-84.
  29. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia. Sep 2006;8(9):708-15.
  30. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. Jan 15 2006;66(2):1234-40.
  31. Williams CD, Whitley BM, Hoyo C, et al. Dietary calcium and risk for prostate cancer: a case-control study among US veterans. Prev Chronic Dis. Jan 2012;9:E39.
  32. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. Feb 2006;15(2):203-10.
  33. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. Dec 7 2005;97(23):1768-77.
  34. Severi G, English DR, Hopper JL, Giles GG. Re: Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. Jun 7 2006;98(11):794-5; author reply 795.
  35. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. Sep 2005;174(3):1065-9; discussion 1069-70.

Autoren und Interessenskonflikte


Stanley A Brosman, MD Clinical Professor, Department of Urology, University of California, Los Angeles, David Geffen School of Medicine
Keine Interessenskonflikte


Mark A Moyad MD, MPH, ND Phil F Jenkins Director of Complementary and Alternative Medicine, Department of Urology, University of Michigan Medical Center
Interessenkonflikt: Abbott Labs (Honorare Sprechen und Lehren); Farr Labs Consulting (Consulting); Guthy Renker Consulting (Consulting); Guthy Renker Royalty (Andere)


Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Interessenkonflikt: Lilly Consulting (Advisor); Astellas Consulting (Sprechen und Lehren); Watson Consulting (Sprechen und Lehren); Allergan Consulting (Sprechen und Lehren)

Weitere Mitarbeiter

Gamal Mostafa Ghoniem, MD, FACS Professor of Urology, Chief, Division of Female Urology, Pelvic Reconstructive Surgery, and Voiding Dysfunction, Department of Urology, University of California, Irvine, School of Medicine
Interessenkonflikt: Astellas Honoraria (Sprechen und Lehren); Coloplasty Consulting (Board membership); Uroplasty Consulting (Consulting)

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Interessenkonflikt: Mitarbeiter von Medscape

Wir bitten darum, Diskussionen höflich und sachlich zu halten. Beiträge werden vor der Veröffentlichung nicht überprüft, jedoch werden Kommentare, die unsere Community-Regeln verletzen, gelöscht.